• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Yield10 Bioscience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

    11/12/24 11:49:02 AM ET
    $YTEN
    Get the next $YTEN alert in real time by email
    yten-20241108
    0001121702FALSE00011217022024-11-082024-11-08

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549
     
    FORM 8-K
     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 
    Date of Report (Date of earliest event reported) November 8, 2024
     
    YIELD10 BIOSCIENCE, INC.
    (Exact name of registrant as specified in its charter)
     

    Delaware001-3313304-3158289
    (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
    19 Presidential Way, Woburn, Massachusetts
     01801
    (Address of principal executive offices)(Zip Code)
     
    Registrant’s Telephone Number, Including Area Code: (617) 583-1700 
    N/A 
    (Former Name or Former Address, if Changed Since Last Report)
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☒ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    None
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company  o
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o






    Item 1.01 Entry into a Material Definitive Agreement.
    On September 5, 2024, Yield10 Bioscience, Inc. (the "Company") issued a promissory note (the "Note") in the principal amount of $3 million, secured by all of the Company's assets, to Nuseed Nutritional US Inc. ("Nuseed"). Effective November 7, 2024, the Company and Nuseed amended the Note to provide that should the Company fail to obtain the Requisite Seller Vote (as defined in the Asset Purchase Agreement between the Company and Nuseed dated October 1, 2024) approving the adoption of the Asset Purchase Agreement by December 2, 2024, an event of default shall occur under the Note, such that the Note will accelerate and all of the $3,000,000 currently due under the Note along with unpaid accrued interest shall become immediately due and payable.
    The Note and Amendment No. 1 to the Note, are attached as exhibits to this Form 8-K, and descriptions of each document are qualified by reference to such exhibits.
    Item 5.07 Submission of Matters to a Vote of Security Holders.
    The information disclosed in Item 8.01 of this Current Report on Form 8-K is incorporated herein by reference.
    Item 8.01 Other Events.
    On November 8, 2024, the Company called to order its Special Meeting of Stockholders, (the “Special Meeting”) for the purpose of approving (i) the sale of substantially all of the assets of the Company pursuant to the Asset Purchase Agreement with Nuseed Nutritional US Inc., dated October 1, 2024 (the “Asset Sale Proposal”), (ii) the liquidation and dissolution of the Company pursuant to a Plan of Complete Liquidation and Dissolution (the “Dissolution Proposal”), (iii) the adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies in the event that there were insufficient votes to approve the Asset Sale or the Dissolution, and (iv) an amendment to the Amended and Restated Certificate of Incorporation, as amended, to effect a decrease in the authorized shares of the Company's common stock from 150,000,000 to 2,000,000.
    The Special Meeting was adjourned without any business being conducted due to lack of the necessary votes to approve the Asset Sale Proposal and the Dissolution Proposal. The Company has determined to keep the polls open and reconvene the Special Meeting on November 21, 2024, at 11 a.m., Eastern Time, in order to provide stockholders additional time to vote on the proposals described in the proxy statement filed with the Securities and Exchange Commission (the “SEC”) on October 16, 2024. At that time, the Special Meeting will be reconvened virtually at https://web.viewproxy.com/yten/2024/. The record date for the Special Meeting remains October 3, 2024. At the time the Special Meeting was adjourned, proxies had been submitted by stockholders representing approximately 59.9% of the shares of the Company’s common stock outstanding and entitled to vote. Proxies previously submitted in respect of the Special Meeting will be voted at the reconvened Special Meeting unless properly revoked, and stockholders who have previously submitted their proxies or otherwise voted and who do not want to change their vote do not need to take any further action.

    No changes have been made to the proposals to be voted on by stockholders at the Special Meeting. The Company strongly encourages all of its stockholders to read the definitive proxy statement it filed with the SEC on October 16, 2024, and other proxy materials relating to the Special Meeting, which are available free of charge on the SEC’s website at www.sec.gov.
    Management of the Company believes that approval of the Asset Sale Proposal and consummation of the transaction with Nuseed is the best alternative for stockholders of the Company to receive any consideration for their shares. If the Company is unable to consummate the transaction with Nuseed, it is unlikely that stockholders will receive any payment in the eventual dissolution of the Company. As such, stockholders are urged to vote their shares in favor of the Asset Sale Proposal as soon as possible.
    Item 9.01 Financial Statements and Exhibits.
    (d) Exhibits.



    Exhibit  
    No. Description
    10.1
    Secured Promissory Note between the Company and Nuseed Nutritional US Inc. dated September 5, 2024
    10.2
    Amendment No. 1 to the Secured Promissory Note between the Company and Nuseed Nutritional US Inc. dated November 7, 2024
    99.1
     Press Release of Yield10 Bioscience, Inc. dated November 8, 2024
    104Cover Page Interactive Data File (embedded within the Inline XBRL document)



    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
      YIELD10 BIOSCIENCE, INC.
       
    November 12, 2024By:/s/ Oliver P. Peoples
      Oliver P. Peoples
      President & Chief Executive Officer


    Get the next $YTEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $YTEN

    DatePrice TargetRatingAnalyst
    2/8/2024Buy → Hold
    Lake Street
    3/10/2022$18.00 → $9.00Buy
    Maxim Group
    More analyst ratings

    $YTEN
    SEC Filings

    See more
    • Yield10 Bioscience Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Costs Associated with Exit or Disposal Activities, Leadership Update, Financial Statements and Exhibits

      8-K - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)

      12/6/24 4:57:07 PM ET
      $YTEN
    • Yield10 Bioscience Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)

      11/22/24 10:39:21 AM ET
      $YTEN
    • Yield10 Bioscience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)

      11/12/24 11:49:02 AM ET
      $YTEN

    $YTEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Yield10 Bioscience Announces Adjournment of Special Meeting of Stockholders to Solicit Sufficient Votes in Favor of the Key Proposals

      Special Meeting Adjourned to Thursday, November 21, 2024 WOBURN, MA / ACCESSWIRE / November 8, 2024 / Yield10 Bioscience, Inc. (OTCQB:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that its Special Meeting of Stockholders (the "Special Meeting"), scheduled to be held at 11:00 a.m., Eastern Time, on November 8, 2024, was convened and adjourned, without any business being conducted, due to lack of sufficient votes in favor of the key proposals related to the Asset Sale to Nuseed and the Dissolution proposal.To pass the proposals, more than 50% of the shares of common stock outstanding and entitled to vote as of the close of business on October 3, 2024

      11/8/24 11:20:00 AM ET
      $YTEN
    • Yield10 Bioscience Announces Second Quarter 2024 Financial Results

      WOBURN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the second quarter ended June 30, 2024. "We continue to work closely with the Nufarm team to finalize the asset purchase agreement announced in July," said Oliver Peoples, Ph.D., President and Chief Executive Officer of Yield10. "We believe that the transition of our Omega-3 Camelina program to Nufarm is in the best interest of our shareholders, business partners, and employees. Receipt of the initial $3 million payment and progress toward earning an additional $2 million milestone payment is enabling

      8/14/24 4:37:26 PM ET
      $YTEN
    • Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of Assets

      WEST SACRAMENTO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (OTC:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that the Company has signed a Memorandum of Understanding ("MOU") and License Agreement with Nuseed Nutritional US Inc. (the seed technologies platform of Nufarm Limited (ASX:NUF)), granting Nufarm a commercial license to certain Omega-3 intellectual property assets, materials and know-how for producing oil in Camelina. Nufarm and Yield10 have additionally agreed to immediately negotiate exclusively with each other for the sale of Yield10's remaining assets to Nufarm. The asset sale will require an affirmative vote

      7/17/24 6:45:00 PM ET
      $YTEN

    $YTEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • VP Research and CSO Snell Kristi covered exercise/tax liability with 877 shares, decreasing direct ownership by 11% to 6,999 units (SEC Form 4)

      4 - YIELD10 BIOSCIENCE, INC. (0001121702) (Issuer)

      8/20/24 3:15:23 PM ET
      $YTEN
    • VP Planning and Communications Brum Lynne H covered exercise/tax liability with 731 shares, decreasing direct ownership by 11% to 5,867 units (SEC Form 4)

      4 - YIELD10 BIOSCIENCE, INC. (0001121702) (Issuer)

      8/19/24 8:11:23 PM ET
      $YTEN
    • VP Finance and CAO Haaser Charles B covered exercise/tax liability with 731 shares, decreasing direct ownership by 11% to 5,949 units (SEC Form 4)

      4 - YIELD10 BIOSCIENCE, INC. (0001121702) (Issuer)

      8/19/24 8:10:36 PM ET
      $YTEN

    $YTEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Yield10 Bioscience Inc. (Amendment)

      SC 13D/A - YIELD10 BIOSCIENCE, INC. (0001121702) (Subject)

      5/23/24 5:51:39 PM ET
      $YTEN
    • SEC Form SC 13D filed by Yield10 Bioscience Inc.

      SC 13D - YIELD10 BIOSCIENCE, INC. (0001121702) (Subject)

      10/11/23 4:05:24 PM ET
      $YTEN
    • SEC Form SC 13D/A filed by Yield10 Bioscience Inc. (Amendment)

      SC 13D/A - YIELD10 BIOSCIENCE, INC. (0001121702) (Subject)

      5/26/23 1:14:08 PM ET
      $YTEN

    $YTEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Schuler Jack W bought $497,250 worth of shares (765,000 units at $0.65) (SEC Form 4)

      4 - YIELD10 BIOSCIENCE, INC. (0001121702) (Issuer)

      10/10/23 4:41:49 PM ET
      $YTEN

    $YTEN
    Financials

    Live finance-specific insights

    See more
    • Yield10 Bioscience Announces Fourth Quarter and Full Year 2023 Financial Results

      -Granted global commercial license to Vision Bioenergy for Camelina addressing the biofuel market-Advanced regulatory and seed scale-up program for omega-3 Camelina-E3902 oil trait in Camelina cleared by regulatory authority for planting in Canada-Management will host a conference call today at 4:30 p.m. (ET) to review financial results and provide a corporate update WOBURN, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the fourth quarter and full year ended December 31, 2023. "In 2023 we successfully executed our plan and achieved several

      4/1/24 4:01:07 PM ET
      $YTEN
    • Yield10 Bioscience to Announce Fourth Quarter and Full Year 2023 Financial Results and Host a Conference Call on Monday, April 1, 2024

      WOBURN, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that the Company will report its fourth quarter and full year 2023 financial results and provide a corporate update on Monday, April 1, 2024. Management will host a conference call on Monday, April 1, 2024.at 4:30 p.m. ET to review financial results, share corporate highlights, and provide an overall business update. Following management's formal remarks, there will be a question and answer session. Interested parties within the U.S. should call 1-877-709-8150 or +1-201-689-8354 (international) to listen to the call. Th

      3/28/24 4:01:20 PM ET
      $YTEN
    • Yield10 Bioscience to Announce Third Quarter 2023 Financial Results and Host a Conference Call on Tuesday, November 14, 2023

      WOBURN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that the Company will report its third quarter 2023 financial results and provide a corporate update on Tuesday, November 14, 2023. Management will host a conference call on Tuesday, November 14, 2023 at 4:30 p.m. ET to review financial results, share corporate highlights, and provide an overall business update. Following management's formal remarks, there will be a question and answer session. Interested parties within the U.S. should call 1-800-715-9871 or +1-646-307-1963 (international) to listen to the call. The Conf

      11/8/23 8:31:35 AM ET
      $YTEN

    $YTEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Yield10 Bioscience Appoints Willie Loh, Ph.D., Former Cargill Executive, to the Board of Directors

      WOBURN, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that Willie Loh, Ph.D., was named to the Company's Board of Directors effective October 4, 2022. Dr. Loh previously served as a Special Commercial and Technical Advisor to the Company. Dr. Loh was formerly Vice President, Market Development of Cargill Inc.'s Global Edible Oils Solutions group in North America. Cargill is a global food and agriculture company. "We are delighted that Willie is expanding his role with Yield10 by serving on our Board of Directors," said Oliver Peoples, Ph.D., Chief Executive Officer of Yield1

      10/5/22 8:30:20 AM ET
      $YTEN

    $YTEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Yield10 Bioscience downgraded by Lake Street

      Lake Street downgraded Yield10 Bioscience from Buy to Hold

      2/8/24 7:25:58 AM ET
      $YTEN
    • Maxim Group reiterated coverage on Yield10 Bioscience with a new price target

      Maxim Group reiterated coverage of Yield10 Bioscience with a rating of Buy and set a new price target of $9.00 from $18.00 previously

      3/10/22 9:38:04 AM ET
      $YTEN
    • Maxim Group reiterated coverage on Yield10 Bioscience with a new price target

      Maxim Group reiterated coverage of Yield10 Bioscience with a rating of Buy and set a new price target of $24.00 from $12.00 previously

      2/9/21 4:14:42 PM ET
      $YTEN